When researchers published the SURMOUNT-1 trial in 2022, the numbers stopped people cold. Participants taking tirzepatide — the active ingredient in Mounjaro — lost an average of 20.9% of their body weight over 72 weeks, a figure that rivaled bariatric surgery outcomes. Semaglutide, the drug behind Ozempic, had already stunned the medical world with its own landmark STEP-1 trial showing average weight loss of 14.9%. Both numbers are remarkable. But they’re not the same number — and understanding why gets to the heart of what separates these two medications at a biological level.
Ozempic (semaglutide) and Mounjaro (tirzepatide) are often lumped together in conversation as “the weight loss shots,” but their mechanisms are meaningfully different, and those differences matter for anyone trying to make an informed decision about their metabolic health.
How Each Drug Actually Works
Semaglutide is a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone your gut naturally releases after eating. It signals your pancreas to release insulin, tells your liver to slow glucose production, and — critically — crosses the blood-brain barrier to reduce appetite and slow gastric emptying. Ozempic mimics this hormone with a long-acting synthetic version designed to stay active for roughly a week after injection. The result is reduced hunger, improved blood sugar regulation, and, for most people, significant weight loss over time.
Tirzepatide does all of that, and then some. It’s what’s called a dual agonist — it activates both GLP-1 receptors and GIP receptors. GIP, or glucose-dependent insulinotropic polypeptide, is another incretin hormone that works alongside GLP-1 but through different pathways. Research suggests that combining GIP and GLP-1 activation produces a synergistic effect on fat metabolism and insulin sensitivity that neither hormone achieves alone. In plain terms: Mounjaro hits two targets instead of one, which appears to explain its superior weight loss outcomes in head-to-head data.
A 2023 observational study published in JAMA Internal Medicine compared real-world outcomes between the two drugs and found that tirzepatide users lost significantly more weight at 3, 6, and 12 months compared to semaglutide users — reinforcing what the clinical trials had suggested.
Side Effects, Tolerability, and What to Expect
Both medications share a similar side effect profile rooted in their shared GLP-1 activity. Nausea, constipation, and GI discomfort are the most commonly reported issues, typically peaking during the dose escalation phase and improving over time. In the SURMOUNT-1 trial, roughly 37% of tirzepatide users at the highest dose reported nausea — comparable to what semaglutide users experience. Neither drug is free of adjustment symptoms, but most people find them manageable when doses are increased gradually.
One issue that deserves serious attention regardless of which medication someone uses is muscle loss. GLP-1-driven caloric restriction is aggressive, and studies have shown that a significant portion of weight lost on these medications can come from lean mass, not just fat. This makes adequate protein intake — most experts suggest at least 1.6 grams per kilogram of body weight daily — and consistent resistance training non-negotiable if preserving muscle is a priority. These medications create a caloric deficit; what you do with that deficit, nutritionally and physically, determines the quality of the weight you lose.
On the approval and cost front, both drugs are FDA-approved for type 2 diabetes management under their original brand names (Ozempic and Mounjaro). Their weight-loss-specific counterparts — Wegovy (semaglutide) and Zepbound (tirzepatide) — carry FDA approval specifically for obesity. Insurance coverage varies widely, and out-of-pocket costs can run several hundred to over a thousand dollars monthly without coverage.
The Takeaway
Mounjaro’s dual-hormone mechanism gives it a measurable edge in weight loss outcomes based on current evidence. Ozempic remains highly effective and has a longer track record of real-world use. Neither drug is a replacement for the fundamentals — strength training, high-protein nutrition, adequate sleep, and stress management remain the infrastructure that determines long-term metabolic health. What these medications can do is lower the physiological barrier to getting started, reduce appetite-driven setbacks, and accelerate results when used alongside those fundamentals. If you’re considering either option, the conversation starts with your physician — but understanding the biology puts you in a better position to have it.